Examples of using Flebogammadif in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Flebogammadif?
Flebogammadif is indicated for.
Do not use Flebogammadif.
Flebogammadif 50 mg/ ml solution for infusion Human normal immunoglobulin IVIg.
Other information about Flebogammadif.
What Flebogammadif contains.
If you have any question about use of Flebogammadif please ask your doctor.
Do not use Flebogammadif if you notice that the solution is cloudy or has deposits.
At the beginning of your infusion you will receive Flebogammadif at a slow rate 0.01-0.02 ml/ kg/ min.
Do not use Flebogammadif if you notice that the solution is cloudy or has deposits.
For the full list of all side effects reported with Flebogammadif, see the Package Leaflet.
How is Flebogammadif used?
The European Commission granted amarketing authorisation valid throughout the European Union for Flebogammadif to Instituto Grifols, S. A. on 23 August 2007.
How has Flebogammadif been studied?
Some side effects are more likely to occur when using ahigh rate of infusion, in patients with low immunoglobulin levels, or in patients who have not received Flebogammadif before or for a long time.
This confirmed that Flebogammadif is effective in immunomodulation.
Flebogammadif 50 mg/ ml solution for infusion Human normal immunoglobulin For intravenous use.
Certain adverse reactions may occur more frequently:• in case of high rate of infusion.• if you have hypo- or agammaglobulinaemia(a condition implying low immunoglobulin levels in your blood) withor without IgA deficiency.• if you are having Flebogammadif for the first time, or it is a long time since your last infusion e. g. several weeks.
If you get more Flebogammadif than you should, your body may take on too much fluid.
Flebogammadif must not be used in patients who are intolerant to fructose a type of sugar.
Ingredients of Flebogammadif see special warnings about excipients at the end of this section.
Flebogammadif is supplied as 0.5 g/ 10 ml, 2.5 g/ 50 ml, 5 g/ 100 ml, 10 g/ 200 ml and 20 g/ 400 ml vials.
The antibodies in Flebogammadif help to stop infections and help to stop your body rejecting the new cells.
Flebogammadif may reduce the effectiveness of certain type of vaccines such as measles, rubella, mumps and varicella.
Two clinical trials were performed with Flebogammadif, one for replacement therapy in patients with primary immunodeficiency(both in adults and in children above 10 years) and another for immunomodulation in adults patients with immune thrombocytopenic purpura.
Flebogammadif should be infused intravenously at an initial rate of 0.01- 0.02 ml/ kg/ min for the first thirty minutes.
Since Flebogammadif might induce dizziness, patients should be cautioned when driving or operating machines.
Flebogammadif is made like Flebogamma, another medicine containing human normal immunoglobulin, with some additional steps in the purification of the product from human plasma.
Flebogammadif is used in three main groups of patients:• Patients who are at risk of infection because they do not have sufficient antibodies proteins naturally found in the blood that help the body to fight infections and other diseases.
Flebogammadif should not be used in people who may be allergic to normal human immunoglobulin or any of the other ingredients, or in patients who are allergic to other types of immunoglobulin, especially where they have deficiency(very low levels) of immunoglobulin A(IgA) and they have antibodies against IgA.